Miloslav Beran

8.0k citations

106 papers · 5.6k indexed · h-index 38

Impact in

Hematology top 0.1%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
Genetics top 0.2%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

Hematology 72
- Acute Myeloid Leukemia Research 58
- Chronic Myeloid Leukemia Treatments 21
Genetics 49
- Chronic Lymphocytic Leukemia Research 43

Co-authors: Hagop M. Kantarjian Elihu H. Estey Charles Koller Michael J. Keating Susan O’Brien Francis J. Giles Jörge E. Cortes William Plunkett
Journals: Blood (40 papers)Cancer (7 papers)Journal of Clinical Oncology (6 papers)Leukemia Research (5 papers)Leukemia (4 papers)
Partner nations: United States United Kingdom Sweden

In The Last Decade

Miloslav Beran

106 papers receiving 5.4k citations

Peers

Countries citing papers authored by Miloslav Beran

Since Specialization

Citations

This map shows the geographic impact of Miloslav Beran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miloslav Beran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miloslav Beran more than expected).

Fields of papers citing papers by Miloslav Beran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miloslav Beran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miloslav Beran. The network helps show where Miloslav Beran may publish in the future.

Co-authors

The 25 scholars most cited alongside Miloslav Beran, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Miloslav Beran Line = papers co-authored together Miloslav Beran links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Chronic Myelomonocytic Leukemia PubMed ·Miloslav Beran	2007	9
2	Prognostic factors and risk assessment in chronic myelomonocytic leukemia: Validation study of the M.D. Anderson Prognostic Scoring System Leukemia & lymphoma ·Miloslav Beran, Sijin Wen, Yu Shen, Francesco Onida, Jaroslav Jelı́nek, Jörge E. Cortes, Francis J. Giles, Hagop M. Kantarjian	2007	45
3	Long‐term follow‐up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome Cancer ·Hagop M. Kantarjian, Miloslav Beran, Jörge E. Cortes, Susan O’Brien, Francis J. Giles, Sherry Pierce, Jianqin Shan, William Plunkett, Michael J. Keating, Elihu H. Estey	2006	75
4	Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia Leukemia Research ·Mignon L. Loh, Simone Martinelli, Viviana Cordeddu, Osman Yuksel, Shashaank Vattikuti, Connie M. Lee, Michael Wulfert, Ulrich Germing, Peter Haas, Charlotte M. Niemeyer, Miloslav Beran, Sara S. Strom, Michael Lübbert, M Sorcini, Elihu H. Estey, Norbert Gattermann, Marco Tartaglia	2004	49
5	FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype Leukemia Research ·Miloslav Beran, Rajyalakshmi Luthra, Hagop M. Kantarjian, Elihu H. Estey	2004	44
6	Phase I study of oral topotecan in hematological malignancies. PubMed ·Miloslav Beran, Susan O’Brien, Deborah A. Thomas, Hai T. Tran, Jörge E. Cortes, Francis J. Giles, Elihu H. Estey, Hagop M. Kantarjian	2003	9
7	Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia Cancer ·Francesco Onida, Greg Ball, Hagop M. Kantarjian, Terry L. Smith, Armand B. Glassman, Maher Albitar, Barbara Scappini, Mary Beth Rios, Michael J. Keating, Miloslav Beran	2002	65
8	Cyclophosphamide, Ara-C and Topotecan (CAT) for Patients With Refractory or Relapsed Acute Leukemia Leukemia & lymphoma ·Jörge E. Cortes, Elihu H. Estey, Miloslav Beran, Susan O’Brien, Francis J. Giles, Arthur Lippoldt, Michael J. Keating, Hagop M. Kantarjian	2000	27
9	Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study Investigational New Drugs ·Norbert Vey, Hagop M. Kantarjian, Miloslav Beran, Susan O’Brien, Jörge E. Cortes, Charles Koller, Elihu H. Estey	1999	28
10	Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy Leukemia ·Steve J. Carter, Robert L. Denton, P I Reed, Hagop M. Kantarjian, Miloslav Beran, Sherry Pierce, MJ Keating	1999	6
11	Ceca–Cyclophosphamide, Etoposide, Carboplatin and Cytosine Arabinoside–A New Salvage Regimen for Relapsed or Refractory Acute Myelogenous Leukemia Leukemia & lymphoma ·Steven M. Kornblau, Hagop M. Kantarjian, Susan O’Brien, Michael Andreeff, GILFRAN MELO NASCIMENTO, Miloslav Beran, Michael J. Keating, Elihu H. Estey	1998	7
12	Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. Journal of Clinical Oncology ·Elihu H. Estey, Peter F. Thall, Michael Andreeff, Miloslav Beran, Hagop M. Kantarjian, Susan O’Brien, D. Byron May, L. E. Robertson, Charles Koller, Steven M. Kornblau	1994	243
13	Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission Cancer ·Hagop M. Kantarjian, Ming Zhang, Susan O’Brien, Elias Anaissie, Miloslav Beran, Sherry Pierce, Fernanda Medina Badilla, Michael J. Keating	1993	19
14	Treatment of Myelodysplastic Syndromes with AML-Type Chemotherapy Leukemia & lymphoma ·Elihu H. Estey, Sherry Pierce, Hagop M. Kantarjian, Susan O’Brien, Miloslav Beran, Michael Andreeff, D. Byron May, Charles Koller, Steven M. Kornblau, Fernanda Medina Badilla, Michael J. Keating	1993	16
15	Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment [see comments] Blood ·S O'Brien, Hagop M. Kantarjian, Miloslav Beran, Terry Smith, Charles Koller, Elihu H. Estey, L. E. Robertson, Susan Lerner, Michael J. Keating	1993	232
16	Phase II Clinical Trial of Fludarabine in Chronic Lymphocytic Leukemia on a Weekly Low-Dose Schedule Leukemia & lymphoma ·Marijke de Boer, Susan O’Brien, Hagop Kantarjian, Fernanda Medina Badilla, Charles Koller, Miloslav Beran, Elihu H. Estey, William Plunkett, Susan Lerner, Michael J. Keating	1993	35
17	Orofacial fungal infections Postgraduate Medicine ·Samuel Dreizen, Michael J. Keating, Miloslav Beran	1992	24
18	Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia Cancer ·Bigar Erbowo, Moshe Talpaz, Michael J. Keating, Elihu H. Estey, Susan O’Brien, Miloslav Beran, K. B. McCredie, J. U. Gutterman, Emil J. Freireich	1991	34
19	Response to salvage therapy and survival after relapse in acute myelogenous leukemia. Journal of Clinical Oncology ·Michael J. Keating, Hagop M. Kantarjian, Terry L. Smith, Elihu H. Estey, R S Walters, Börje S. Andersson, Miloslav Beran, K. B. McCredie, Emil J. Freireich	1989	148
20	Direct cytogenetic evidence of induced maturation of leukemic cells in vivo Proceedings of the American Association for Cancer Research ·WN Hittelman, Misha Hawkins, Iris Edenheiser, Miloslav Beran	1985	5

About Miloslav Beran

Miloslav Beran is a scholar working on Hematology, Genetics, Oncology, Public Health, Environmental and Occupational Health and Pathology and Forensic Medicine, having authored 106 papers that have together received 5.6k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (58 papers), Chronic Lymphocytic Leukemia Research (43 papers), Acute Lymphoblastic Leukemia research (22 papers), Chronic Myeloid Leukemia Treatments (21 papers), Neutropenia and Cancer Infections (15 papers), Lymphoma Diagnosis and Treatment (14 papers), Cancer therapeutics and mechanisms (13 papers) and Retinoids in leukemia and cellular processes (13 papers). The work is most often cited by research in Hematology (3.3k citations), Genetics (2.6k citations), Pathology and Forensic Medicine (1.1k citations), Oncology (1.1k citations) and Immunology (744 citations). Miloslav Beran has collaborated with scholars based in United States, United Kingdom and Sweden. Frequent co-authors include Hagop M. Kantarjian, Elihu H. Estey, Charles Koller, Michael J. Keating, Susan O’Brien, Francis J. Giles, Jörge E. Cortes, William Plunkett, S O'Brien and Srđan Verstovšek. Their work appears in journals such as Blood, Cancer, Journal of Clinical Oncology, Leukemia Research and Leukemia.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact